Evidence map›Paper›PMID 38802618›Full record

ArticleAmerican journal of clinical dermatology2024

Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment.

Sarah E Thomas, Marieke M B Seyger, Josje E Mangnus, Marisol E Otero, Antoni H Gostynski, Marcellus D Njoo, Paul M Ossenkoppele, Inge M Haeck, Judith H J Hendricksen-Roelofzen, John E M Körver and 15 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in American journal of clinical dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Sarah E ThomasDepartment of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, 6500 HB, Nijmegen, The Netherlands. sarah.thomas@radboudumc.nl.ORCID http://orcid.org/0000-0002-1343-353X
Marieke M B SeygerDepartment of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, 6500 HB, Nijmegen, The Netherlands.
Josje E MangnusDepartment of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, 6500 HB, Nijmegen, The Netherlands.
Marisol E OteroDepartment of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, 6500 HB, Nijmegen, The Netherlands.
Antoni H GostynskiDepartment of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands.
Marcellus D NjooDepartment of Dermatology, Ziekenhuisgroep Twente, Almelo, Hengelo, The Netherlands.
Paul M OssenkoppeleDepartment of Dermatology, Ziekenhuisgroep Twente, Almelo, Hengelo, The Netherlands.
Inge M HaeckDepartment of Dermatology, Utrecht Medisch Centrum, Utrecht, The Netherlands.
Judith H J Hendricksen-RoelofzenDepartment of Dermatology, Streekziekenhuis Koningin Beatrix, Winterswijk, The Netherlands.
John E M KörverDepartment of Dermatology, Amphia Ziekenhuis, Breda, The Netherlands.
Sharon R P DodemontDepartment of Dermatology, Catharina Ziekenhuis, Eindhoven, The Netherlands.
Ron A TupkerDepartment of Dermatology, St Antonius Ziekenhuis, Nieuwegein, The Netherlands.
Maartje A M BerendsDepartment of Dermatology, Slingeland Ziekenhuis, Doetinchem, The Netherlands.
Lizelotte M J T Weppner-ParrenDepartment of Dermatology, Jeroen Bosch Ziekenhuis, 's Hertogenbosch, The Netherlands.
Romy R M C KeijsersDepartment of Dermatology, Zuyderland Medisch Centrum, Sittard-Geleen, Heerlen, The Netherlands.
Annet M OostveenDepartment of Dermatology, Gelre Ziekenhuizen, Apeldoorn, The Netherlands.
Bas PetersDepartment of Dermatology, Ziekenhuis Rijnstate, Arnhem, The Netherlands.
Roland MommersDepartment of Dermatology, Anna Ziekenhuis, Geldrop, The Netherlands.
Martijn B A van DoornDepartment of Dermatology, Erasmus MC, Rotterdam, The Netherlands.
Milan TjioeDepartment of Dermatology, Bravis, Bergen op Zoom, The Netherlands/dermaTeam, Middelburg, The Netherlands.
Wendelien R VeldkampDepartment of Dermatology, Ziekenhuis Gelderse Vallei, Ede, The Netherlands.
Astrid L A KuijpersDepartment of Dermatology, Máxima MC, Eindhoven, The Netherlands.
Marloes M KleinpenningDepartment of Dermatology, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands.
Elke M G J de JongDepartment of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, 6500 HB, Nijmegen, The Netherlands.
Juul M P A van den ReekDepartment of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, 6500 HB, Nijmegen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Dermatologic AgentsDrug SubstitutionInterleukin-23PsoriasisUstekinumabAdalimumabAdultAntibodies, Monoclonal, HumanizedFemaleHumansMaleMiddle AgedRetrospective StudiesSeverity of Illness IndexTreatment OutcomeAdalimumabAntibodies, Monoclonal, HumanizedDermatologic AgentsInterleukin-23Ustekinumab

Identifiers

PMID38802618

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.